MBRX Moleculin Biotech Inc.

0.92
+0.01  (+1%)
Previous Close 0.91
Open 0.91
Price To Book 2.2
Market Cap 42,252,395
Shares 45,727,700
Volume 135,173
Short Ratio
Av. Daily Volume 261,133
Stock charts supplied by TradingView

NewsSee all news

  1. Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models

    HOUSTON, Dec. 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting

  2. Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia

    HOUSTON, Dec. 4, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting

  3. Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients

    HOUSTON, Nov. 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting

  4. Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer

    HOUSTON, Nov. 13, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting

  5. Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial

    HOUSTON, Nov. 12, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 interim data presented December 4, 2019.
Annamycin
Acute myeloid leukemia (AML) - cancer
Phase 1 trial initiated.
WP1066
Glioblastoma
Phase 1 initial data demonstrated safety - November 19, 2019.
WP1220
Cutaneous T-Cell Lymphoma (CTCL)

Latest News

  1. Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models

    HOUSTON, Dec. 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting

  2. Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia

    HOUSTON, Dec. 4, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting

  3. Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients

    HOUSTON, Nov. 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting

  4. Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer

    HOUSTON, Nov. 13, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting

  5. Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial

    HOUSTON, Nov. 12, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting

  6. Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2019

    HOUSTON, Nov. 12, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting

  7. Moleculin Announces New Data Confirms Anti-tumor Efficacy of Annamycin in Both Human and Murine AML Models

    HOUSTON, Oct. 29, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting

  8. Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery

    HOUSTON, Sept. 16, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting